Date:____10/12/22_

Your Name:____Jason Zhu__

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | x_None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | x_None | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22__

Your Name:_____Chad Livasy

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | xNone | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____Erin E Donahue

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastxNonexNone | 36 months |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ James T Symanowski

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | xNone | |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ Claud M Grigg

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastxNonexNone | 36 months |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ Landon Brown

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastxNonexNone | 36 months |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony | x_Nonex_Nonex_None |
|----|---|--------------------|
| 7 | Support for attending meetings and/or travel | xNone |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | xNone |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ Justin Matulay

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). Royalties or licenses | Time frame: pastxNonexNone | 36 months |
| 4 | Consulting fees | x_None | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | x_None |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x_None |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ James T Kearns

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| T | All support for the present manuscript (e.g., funding, | xNone | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | xNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | x_None | |
| | | | |
| | | | |
| 4 | Consulting fees | x_None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | x_None |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x_None |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ Derek Raghavan

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| Ŧ | All support for the present manuscript (e.g., funding, | xNone | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | xNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | x_None | |
| | | | |
| | | | |
| 4 | Consulting fees | x_None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | x_None |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x_None |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22_

Your Name:_____ Earle F Burgess

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | xNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Pfizer, Astellas | Payments to institution |
| 3 | Royalties or licenses | xNone | |
| 4 | Consulting fees | x_None | |

| 5 6 7 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending | Exelexis, AstraZenecaxNonexNone | Payments to me |
|-------|--|---|----------------|
| | meetings and/or travel | | |
| 8 | Patents planned, issued or pending | _xNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | xNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Johnson and Johnson | Payments to me |
| 11 | Stock or stock options | Exelexis, Becton Dickinson, Calithera Biosciences, Medtronic, Macrogenics, Arvinas, Autolus | Payments to me |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone | |
| 13 | Other financial or non- financial interests | xNone | |

Dr. Earle Burgess is a primary investigator in several clinical trials for which he receives compensation via grants or contracts from the above organizations. These clinical trials are not related to the subject of this paper, and no companies with which he has relationships with were involved in the design, conception, funding, or writing of this paper.

Please place an "X" next to the following statement to indicate your agreement:

Date:____10/12/22__

Your Name: _____ Peter Clark

Manuscript Title: Prognostic Value of Galectin-1 and Galectin-3 Expression in Localized Urothelial Bladder Cancer Manuscript number (if known):______

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|---|---|
| 1 | All support for the present | | |
| Ŧ | All support for the present manuscript (e.g., funding, | xNone | |
| | provision of study materials, | | |
| | medical writing, article | | |
| | processing charges, etc.) | | |
| | No time limit for this item. | | |
| | | | |
| | | | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | xNone | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | x_None | |
| | | | |
| | | | |
| 4 | Consulting fees | x_None | |
| | | | |
| | | | |

| 5 | Payment or honoraria for lectures, presentations, | x_None |
|----|--|--------|
| | speakers bureaus, manuscript writing or educational events | |
| 6 | Payment for expert testimony | xNone |
| 7 | Support for attending meetings and/or travel | x_None |
| 8 | Patents planned, issued or pending | xNone |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | x_None |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | x_None |
| 11 | Stock or stock options | xNone |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | _xNone |
| 13 | Other financial or non- financial interests | xNone |

No conflicts of interest

Please place an "X" next to the following statement to indicate your agreement: